Research and Clinical Trials
Search Cancer Clinical Trials
Clinical Trials
New Search
| Title | A Study of Pemetrexed & Carboplatin/Cisplatin or Gemcitabine & Carboplatin/Cisplatin With or Without IMC-1121B in Patients Previously Untreated With Recurrent or Advanced Non-small Cell Lung Cancer (NSCLC) |
|---|---|
| Disease/Condition | Lung and Other Thoracic Tumors |
| Description | The purpose of this study is to determine if patients with Stage 4 non-small cell lung cancer have a better outcome when treated with 1121B in combination with pemetrexed + carboplatin/cisplatin or gemcitabine + carboplatin/cisplatin than when treated with pemetrexed + carboplatin/cisplatin or gemcitabine + carboplatin/cisplatin alone. |
| Eligibility Criteria | To be eligible for this study, patients must meet several criteria, including but not limited to the following: * Patient must be 18 Years and older * Subject must have confirmed Non-small Cell Lung Cancer. * Subject must have Stage IV disease at the time of study entry. |
| Principal Investigator | Missak Haigentz, MD |
| Contact Name | Yoko Eng, NP |
| Phone | (718) 920-2090 |
| Contact Email | yeng@montefiore.org |
| Post Date | 07/08/2010 |
| Protocol Number | 10-03-060/West |
| Status | Recruiting |
| Current Trial Type | Interventional |
